The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1

Blood. 2001 May 15;97(10):2941-7. doi: 10.1182/blood.v97.10.2941.

Abstract

The G protein-coupled 7 transmembrane (STM) chemoattractant receptors can be inactivated by heterologous desensitization. Earlier work showed that formly peptide receptor-like 1 (FPRL1), an STM receptor with low affinity for the bacterial chemotactic peptide formyl-methionyl-leucyl-phenylalamine (fMLF), is activated by peptide domains derived from the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp120 and its activation results in desensitization and down-regulation of the chemokine receptors CCR5 and CXCR4 from monocyte surfaces. This study investigated the possibility of interfering with the function of CCR5 or CXCR4 as HIV-1 coreceptors by activating FPRL1. Cell lines were established expressing FPRL1 in combination with CD4/CXCR4 or CD4/CCR5 and the effect of a synthetic peptide, WKYMVm, a potent activator of formyl peptide receptors with preference for FPRL1 was determined. Both CXCR4 and CCR5 were desensitized by activation of the cells with WKYMVm via a staurosporine-sensitive pathway. This desensitization of CXCR4 and CCR5 also attenuated their capacity as the fusion cofactors for HIV-1 envelope glycoprotein and resulted in a significant inhibition of p24 production by cell lines infected with HIV-1 that use CCR5 or CXCR4 as coreceptors. Furthermore, WKYMVm inhibited the infection of human peripheral monocyte-derived macrophages and CD4(+) T lymphocytes by R5 or X4 strains of HIV-1, respectively. These results indicate that heterologous desensitization of CCR5 and CXCR4 by an FPRL1 agonist attenuates their major biologic functions and suggest an approach to the development of additional anti-HIV-1 agents. (Blood. 2001;97:2941-2947)

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antiviral Agents / pharmacology
  • CD4-Positive T-Lymphocytes / virology
  • Cells, Cultured
  • Gene Expression
  • HIV Envelope Protein gp120 / genetics
  • HIV Envelope Protein gp120 / physiology
  • HIV-1 / drug effects
  • HIV-1 / physiology
  • Humans
  • Macrophages / virology
  • Monocyte Chemoattractant Proteins / pharmacology*
  • Oligopeptides / pharmacology*
  • Osteosarcoma
  • Receptors, CCR5 / drug effects*
  • Receptors, CCR5 / physiology
  • Receptors, CXCR4 / drug effects*
  • Receptors, CXCR4 / physiology
  • Receptors, Formyl Peptide
  • Receptors, HIV / genetics
  • Receptors, Immunologic / drug effects*
  • Receptors, Immunologic / genetics
  • Receptors, Immunologic / physiology*
  • Receptors, Lipoxin*
  • Receptors, Peptide / drug effects*
  • Receptors, Peptide / genetics
  • Receptors, Peptide / physiology*
  • Transfection
  • Tumor Cells, Cultured

Substances

  • Antiviral Agents
  • FPR2 protein, human
  • HIV Envelope Protein gp120
  • Monocyte Chemoattractant Proteins
  • Oligopeptides
  • Receptors, CCR5
  • Receptors, CXCR4
  • Receptors, Formyl Peptide
  • Receptors, HIV
  • Receptors, Immunologic
  • Receptors, Lipoxin
  • Receptors, Peptide
  • Trp-Lys-Tyr-Met-Val-Met